Teva and Prestige Biopharma Forge Partnership for Tuznue®
Teva Pharmaceuticals has secured a license and supply agreement with Prestige Biopharma, focusing on the commercialization of Tuznue®, a biosimilar to the established Herceptin® (trastuzumab). This collaboration marks a significant step in enhancing patient access to treatment options in Europe.
Understanding Tuznue®
Tuznue® is designed to be a cost-effective therapy, showing similar efficacy and safety as its branded counterpart, Herceptin®. It is specifically indicated for patients facing HER2-positive metastatic breast cancer, HER2-positive early breast cancer, and HER2-positive metastatic gastric cancer. The European Commission granted marketing authorization for Tuznue®, allowing more patients to benefit from this innovative treatment.
A Collaboration of Expertise
Under the new agreement, Teva will leverage its extensive commercial network to market and distribute Tuznue® across a majority of European countries. Prestige Biopharma will handle the production, ensuring high-quality supply from its state-of-the-art, EU-GMP-certified manufacturing facility, well-equipped for modern biosimilars.
“Our collaboration with Prestige signifies a shared commitment to advancing health care through biosimilars,” said Richard Daniell, Executive Vice President for European Commercial at Teva. “This partnership will unlock new potential for patients in Europe, ensuring they receive vital medications efficiently.”
The Vision of Prestige Biopharma
Lisa Park, CEO of Prestige Biopharma, expressed enthusiasm for the partnership: “Teva’s strong market presence will propel the launch of Tuznue® across Europe, elevating our goal to emerge as a leader in this essential sector. With Teva’s support, we can enhance our pipeline that includes bevacizumab and several other candidates.” This agreement emphasizes a collective effort toward enhancing healthcare access through biosimilars.
Tuznue®: A Boon for Patients
As a biosimilar, Tuznue® aims to replicate the effectiveness of Herceptin® while also offering a more accessible price point, thus opening doors for many patients. The approval signifies an important breakthrough in the biosimilar landscape, allowing for broader access to necessary medications for treating severe health conditions.
About Teva Pharmaceutical Industries
Teva, established over 120 years ago, stands at the forefront of the biopharmaceutical industry. Rooted in a commitment to enhance patient health, Teva integrates innovation within neuroscience, immunology, and complex generics, ensuring they are adept at meeting patient needs globally.
About Prestige Biopharma
Founded in 2015 in Singapore, Prestige Biopharma operates a dedicated GMP manufacturing facility in Korea, which showcases a production capacity of 154,000 liters. The company is actively engaged in developing groundbreaking biosimilars and antibody drugs, aiming for substantial impact in the global biopharmaceutical market.
Frequently Asked Questions
What is Tuznue®?
Tuznue® is a biosimilar to Herceptin® (trastuzumab), approved for treating HER2-positive conditions, such as breast and gastric cancers.
Who are the partners in this agreement?
Teva Pharmaceuticals and Prestige Biopharma are the primary partners in this significant licensing agreement for Tuznue® commercialization.
What markets will Tuznue® be available in?
Tuznue® will be marketed and distributed by Teva across a majority of European markets, enhancing access for patients.
What role does Prestige Biopharma play?
Prestige Biopharma will be responsible for production and supply of Tuznue® using its advanced manufacturing capabilities.
How does this partnership impact patients?
This collaboration will facilitate greater access to effective cancer treatments, aligning with the companies' commitment to improving healthcare outcomes.
